Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysis
- PMID: 37500985
- DOI: 10.1007/s00280-023-04569-w
Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysis
Abstract
Purpose: Because of the large interindividual variability of afatinib pharmacokinetics and adverse events, we evaluated the effects of polymorphisms in pregnane X receptor (NR1I2) and ABC transporters (ABCB1, ABCG2, and ABCC2) on the pharmacokinetics of afatinib.
Methods: The steady-state area under the concentration-time curve (AUC)0-24 of afatinib was analyzed using blood sampling just prior to and at 1, 2, 4, 6, 8, 12, and 24 h on day 15 after administration.
Results: The median oral clearance (CL/F) of afatinib in patients with the NR1I2 7635A allele was significantly lower than those in patients with the 7635G/G genotype (42.0 and 60.0 L/h, respectively, P = 0.025). There were no significant differences in afatinib CL/F between genotypes for NR1I2 8055C > T, -25385C > T, ABCB1, ABCG2, and ABCC2 polymorphisms. Based on the area under the receiver-operating characteristic curve, the threshold afatinib AUC0-24 value for prediction of dose reduction or withdrawal was 689 ng·h/mL at the best sensitivity (81.0%) and specificity (72.7%). In multivariate logistic regression analysis, an afatinib AUC0-24 above 689 ng·h/mL was independently associated with increased risk of dose reduction or withdrawal (OR: 11.66, P = 0.012).
Conclusions: The NR1I2 7635A allele was related to a lower afatinib CL/F. Based on the AUC of 689 ng h/mL and CL/F, the optimal doses for patients with the NR1I2 7635G/G genotype and 7635A allele were recommended to be set at 40 and 30 mg/day, respectively, and subsequent adjustment of the maintenance dose based on the plasma concentrations of afatinib may be necessary to avoid afatinib-related adverse events.
Keywords: ABC transporter; Afatinib; Area under the plasma concentration–time curve; Exposure; Pregnane X receptor.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer.Invest New Drugs. 2022 Dec;40(6):1254-1262. doi: 10.1007/s10637-022-01304-9. Epub 2022 Sep 23. Invest New Drugs. 2022. PMID: 36149549
-
Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.Lung Cancer. 2019 Aug;134:1-6. doi: 10.1016/j.lungcan.2019.05.013. Epub 2019 May 18. Lung Cancer. 2019. PMID: 31319966
-
Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.Med Oncol. 2018 May 7;35(6):90. doi: 10.1007/s12032-018-1146-z. Med Oncol. 2018. PMID: 29736778
-
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1337-54. doi: 10.1517/17425255.2014.952630. Epub 2014 Aug 27. Expert Opin Drug Metab Toxicol. 2014. PMID: 25162314 Review.
-
Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition.Curr Drug Targets. 2011 May;12(5):631-46. doi: 10.2174/138945011795378487. Curr Drug Targets. 2011. PMID: 21039333 Review.
References
-
- Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702–4711. https://doi.org/10.1038/onc.2008.109 - DOI - PubMed - PMC
-
- Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342–350. https://doi.org/10.1124/jpet.112.197756 - DOI - PubMed
-
- Sequist LV, Yang JC-H, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334. https://doi.org/10.1200/jco.2012.44.2806 - DOI - PubMed
-
- Wu Y-L, Zhou C, Hu C-P et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222. https://doi.org/10.1016/s1470-2045(13)70604-1 - DOI - PubMed
-
- Yang JC-H, Wu Y-L, Schuler M et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16:141–151. https://doi.org/10.1016/s1470-2045(14)71173-8 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical